Clonazepam intranasal

Drug Profile

Clonazepam intranasal

Alternative Names: JZP-8

Latest Information Update: 25 Jun 2015

Price : $50

At a glance

  • Originator Jazz Pharmaceuticals
  • Developer Jazz Pharmaceuticals plc
  • Class Antiepileptic drugs; Antipsychotics; Anxiolytics; Benzodiazepines; Benzodiazepinones
  • Mechanism of Action GABA A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Epilepsy
  • New Molecular Entity No

Highest Development Phases

  • No development reported Epilepsy

Most Recent Events

  • 25 Jun 2015 No recent reports of development identified - Phase-II for Epilepsy in Finland and USA (Intranasal)
  • 18 Jan 2012 Azur Pharma has merged with Jazz Pharmaceuticals Inc to form Jazz Pharmaceuticals plc
  • 10 Mar 2011 Jazz Pharmaceuticals is no longer actively seeking a licensing partner for clonazepam intranasal
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top